Impressive Results for RSV Protection
Our researchers led an Australian-first study demonstrating the effectiveness of a long-acting monoclonal antibody, Nirsevimab, which was provided to babies as part of WA’s nation-leading RSV immunisation program in 2024. Funded by Perth Children’s Hospital Foundation, the REVIVE Study found Nirsevimab to be almost 90 per cent effective in reducing hospitalisation rates and helped more than 500 WA families avoid a hospital stay.
Perth Mum Charlotte, pictured above, was very pleased her twins Finn and Ember were some of WA's first babies to receive protection against RSV. Read more about the results online here.
A second long-acting monoclonal antibody for RSV, Clesrovimab, investigated by the Vaccines Trials Group, has been licensed in the US and Europe, with plans for it to be available in Australia soon.
STREETON Study - STudy of Real world vaccinE Effectiveness of maTernal RSVpreF vaccinatiON against respiratory syncytial virus (RSV) in hospitalised infants in Australia
The STREETON study is examining how well the maternal RSV vaccine, Abrysvo, protects infants from serious RSV illness. Abrysvo has been available nationwide under the National Immunisation Program since early 2025, and this study is designed to measure its real‑world effectiveness by reviewing hospital and immunisation records.
With nine sites contributing data across the country, the project represents one of the largest coordinated RSV evaluations in Australia. Findings from the STREETON study will help guide future vaccine policy to keep the youngest ones in our communities healthy and safe.